Halozyme Therapeutics (HALO) Research & Development (2010 - 2026)
Halozyme Therapeutics (HALO) posted quarterly Research & Development of $25.6 million for Q1 2026, up 72.71% year-over-year from $14.8 million in Q1 2025, and down 19.87% quarter-over-quarter from $31.9 million in Q4 2025.
Halozyme Therapeutics (HALO) Research & Development (2010 - 2026) Analysis & Trends
Halozyme Therapeutics (HALO) has reported Research & Development for 17 consecutive years, with $25.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Research & Development rose 72.71% year-over-year to $25.6 million; the TTM figure through Mar 2026 stood at $92.3 million (up 23.44% YoY), while the FY2025 annual figure was $81.5 million, up 3.09% from the prior year.
- Research & Development declined to $25.6 million in Q1 2026 per HALO's latest filing, from $31.9 million in the prior quarter.
- Across five years, Research & Development topped out at $31.9 million in Q4 2025 and bottomed at $11.9 million in Q1 2022.
- Historically, Research & Development has averaged $19.4 million across 5 years, with a median of $18.5 million in 2024.
- Annual changes were most pronounced in 2022 — Research & Development soared 123.25% — and 2025, when it fell 22.56%.
- Halozyme Therapeutics' Research & Development stood at $22.6 million in 2022, then dropped by 5.45% to $21.3 million in 2023, then dropped by 4.19% to $20.4 million in 2024, then soared by 56.04% to $31.9 million in 2025, then dropped by 19.87% to $25.6 million in 2026.
- Business Quant data shows HALO's Research & Development at $25.6 million in Q1 2026, $31.9 million in Q4 2025, and $17.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Halozyme Therapeutics | 11.25 Bn | 11.02 Bn | 401.83 Mn | 27.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 27.66 Mn |
| Mar 31, 2026 | 25.56 Mn |
| Dec 31, 2025 | 31.90 Mn |
| Sep 30, 2025 | 17.25 Mn |
| Jun 30, 2025 | 17.54 Mn |
| Mar 31, 2025 | 14.80 Mn |
| Dec 31, 2024 | 20.44 Mn |
| Sep 30, 2024 | 18.46 Mn |
| Jun 30, 2024 | 21.04 Mn |
| Mar 31, 2024 | 19.11 Mn |
| Dec 31, 2023 | 21.34 Mn |
| Sep 30, 2023 | 17.32 Mn |
| Jun 30, 2023 | 19.73 Mn |
| Mar 31, 2023 | 17.98 Mn |
| Dec 31, 2022 | 22.57 Mn |
| Sep 30, 2022 | 16.71 Mn |
| Jun 30, 2022 | 15.48 Mn |
| Mar 31, 2022 | 11.85 Mn |
| Dec 31, 2021 | 10.11 Mn |
| Sep 30, 2021 | 8.49 Mn |